CLSN Celsion Corporation Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

CLSN [NASD]

Celsion Corporation

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-0.86	Insider Own	1.00%	Shs Outstand	25.80M	Perf Week	-7.33%
Market Cap	79.98M	Forward P/E	-	EPS next Y	-0.23	Insider Trans	1.77%	Shs Float	28.77M	Perf Month	120.63%
Income	-19.50M	PEG	-	EPS next Q	-0.11	Inst Own	13.90%	Short Float	0.39%	Perf Quarter	139.66%
Sales	0.50M	P/S	159.96	EPS this Y	-14.20%	Inst Trans	221.20%	Short Ratio	0.10	Perf Half Y	91.72%
Book/sh	0.63	P/B	4.41	EPS next Y	57.90%	ROA	-48.40%	Target Price	-	Perf Year	69.51%
Cash/sh	0.54	P/C	5.13	EPS next 5Y	-	ROE	-120.10%	52W Range	0.69 - 3.65	Perf YTD	62.57%
Dividend	-	P/FCF	-	EPS past 5Y	47.50%	ROI	-76.80%	52W High	-23.84%	Beta	2.39
Dividend %	-	Quick Ratio	2.50	Sales past 5Y	0.00%	Gross Margin	-	52W Low	304.95%	ATR	0.28
Employees	29	Current Ratio	2.50	Sales Q/Q	0.00%	Oper. Margin	-	RSI (14)	71.37	Volatility	8.81% 14.59%
Optionable	Yes	Debt/Eq	0.61	EPS Q/Q	-58.10%	Profit Margin	-	Rel Volume	0.61	Prev Close	2.86
Shortable	Yes	LT Debt/Eq	0.47	Earnings	May 15 BMO	Payout	-	Avg Volume	1.12M	Price	2.78
Recom	1.80	SMA20	31.82%	SMA50	85.64%	SMA200	85.40%	Volume	678,904	Change	-2.80%

Oct-04-17

Upgrade

Maxim Group

Hold → Buy

Apr-10-17

Resumed

Rodman & Renshaw

Buy

$1.50

Nov-10-16

Downgrade

Maxim Group

Buy → Hold

Jul-12-16

Resumed

H.C. Wainwright

Buy

Jan-19-16

Reiterated

Maxim Group

Buy

$12 → $9

Jul-15-15

Initiated

Maxim Group

Buy

$12

Jan-10-14

Resumed

HC Wainwright

Buy

$5 → $8

Aug-16-12

Reiterated

Griffin Securities

Buy

$10 → $18

Feb-16-12

Initiated

Brean Murray

Buy

Oct-26-11

Initiated

Rodman & Renshaw

Mkt Outperform

Nov-11-09

Initiated

Needham

Buy

May-29-20 08:30AM	Celsion Reports Data Safety Monitoring Board Recommendation to Proceed to Phase II of the OVATION 2 Study in Advanced Ovarian Cancer GlobeNewswire
May-15-20 08:00AM	Celsion Corporation Reports First Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
May-08-20 09:00AM	Celsion Corporation to Hold First Quarter 2020 Financial Results Conference Call on Friday, May 15, 2020 GlobeNewswire
Apr-23-20 08:30AM	Celsion Receives $2.5 Million in Non-Dilutive Funding from the Sale of its New Jersey State Net Operating Losses and Grant Funding Under the Paycheck Protection Program GlobeNewswire +6.25%
Apr-17-20 10:04AM	If You Had Bought Celsion (NASDAQ:CLSN) Stock Five Years Ago, You'd Be Sitting On A 97% Loss, Today Simply Wall St.
Apr-15-20 08:30AM	Celsion Reports that Sufficient Events Have Been Reached for the Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer GlobeNewswire +6.36%
Apr-04-20 06:13AM	Edited Transcript of CLSN earnings conference call or presentation 26-Mar-20 3:00pm GMT Thomson Reuters StreetEvents
Mar-26-20 09:00AM	Celsion Corp. to Host Earnings Call ACCESSWIRE -7.01%
08:00AM	Celsions OVATION 1 Study with GEN-1 in Ovarian Cancer Shows Strong Progression-Free Survival Treatment Effect Utilizing Medidata Synthetic Control Arm GlobeNewswire
Mar-25-20 04:15PM	Celsion Corporation Reports 2019 Financial Results and Provides Business Update GlobeNewswire +8.74%
Mar-23-20 08:00AM	Celsions GEN-1 Immunotherapy Receives Orphan Drug Designation from the European Medicines Agency GlobeNewswire +19.75%
Mar-19-20 08:30AM	Celsion Corporation to Hold Year-End 2019 Financial Results Conference Call on Thursday, March 26, 2020 GlobeNewswire +10.63%
08:00AM	Celsion Announces Highly Encouraging Initial Clinical Results from the Phase I Portion of the Phase I/II OVATION 2 Study with GEN-1 in Patients with Advanced Ovarian Cancer GlobeNewswire
Mar-03-20 08:30AM	Celsion CEO Issues Letter to Stockholders GlobeNewswire
Feb-28-20 08:45AM	Celsion Corporation Prices $4.8 Million Registered Direct Offering GlobeNewswire -16.13%
Feb-25-20 06:20AM	When Can We Expect A Profit From Celsion Corporation (NASDAQ:CLSN)? Simply Wall St. -9.38%
Feb-06-20 09:25AM	Celsion Corporation Announces DSMB has Confirmed Initial Safety of Weekly GEN-1 Dosing at 100 mg/m² in 15 Randomized Patients with Advanced Ovarian Cancer GlobeNewswire
Feb-04-20 08:30AM	Principal Investigator Professor Riccardo Lencioni Presents Celsion ThermoDox® Trial Data at SPECTRUM 2020 Interventional Oncology Conference GlobeNewswire
Jan-20-20 05:41AM	Does Celsion Corporation (NASDAQ:CLSN) Have A High Beta? Simply Wall St.
Jan-15-20 04:34PM	Alexion to Start Pivotal Study on Ultomiris for ALS in Q1 Zacks
08:22AM	Momenta (MNTA) Provides Pipeline Updates, Stock Rallies Zacks
Jan-14-20 08:53AM	Ultragenyx Provides Preliminary Crysvita 2019 Revenues Zacks
Jan-09-20 04:47PM	Applied Therapeutics Up on Positive Galactosemia Study Data Zacks
Jan-07-20 09:59AM	Protagonist (PTGX) Starts Study on PTG-300 for Blood Disorder Zacks
09:19AM	aTyr (LIFE) Surges on Collaboration Deal With Kyorin Pharma Zacks
Dec-23-19 02:15PM	Hedge Funds Have Never Been This Bullish On Celsion Corporation (CLSN) Insider Monkey
Dec-18-19 08:00AM	Celsions New Subsidiary in China to Serve as Beachhead for Commercializing ThermoDox® in China and Southeast Asia GlobeNewswire -6.67%
Dec-17-19 08:00AM	Celsion Receives $2.0 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program GlobeNewswire
Dec-15-19 08:10AM	Should You Be Pleased About The CEO Pay At Celsion Corporation's (NASDAQ:CLSN) Simply Wall St.
Nov-30-19 01:48AM	Edited Transcript of CLSN earnings conference call or presentation 15-Nov-19 4:00pm GMT Thomson Reuters StreetEvents
Nov-14-19 04:05PM	Celsion Corporation Reports Third Quarter 2019 Financial Results and Provides Business Update GlobeNewswire +28.69%
08:00AM	Celsion Announces Publication of Research on Fluorescence Imaging of ThermoDox® Uptake in International Journal of Hyperthermia GlobeNewswire
Nov-09-19 08:40AM	If You Had Bought Celsion (NASDAQ:CLSN) Stock Five Years Ago, You'd Be Sitting On A 96% Loss, Today Simply Wall St.
Nov-08-19 08:30AM	Celsion Corporation to Hold Third Quarter 2019 Financial Results Conference Call on Friday, November 15, 2019 GlobeNewswire
Nov-05-19 08:00AM	Celsion Announces DSMB Recommendation to Continue GEN-1 at 100mg/m² Dose to Complete the Phase I Portion of OVATION 2 Study in Ovarian Cancer GlobeNewswire -9.20%
Nov-04-19 08:00AM	Celsion Reports Unanimous Independent Data Monitoring Committee Recommendation to Continue the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer GlobeNewswire
Oct-04-19 07:52AM	Is Celsion (NASDAQ:CLSN) Using Debt In A Risky Way? Simply Wall St.
Oct-01-19 08:00AM	Celsion Strengthens Its 2019 Balance Sheet with the Approval of Its Application to Sell Net Operating Losses for $2.1 Million in Non-Dilutive Funding GlobeNewswire
Sep-30-19 02:30PM	Celsion to Present at the Chardan 3rd Annual Genetic Medicines Conference GlobeNewswire
Sep-23-19 08:00AM	Celsion Co-sponsors Hepatocellular Carcinoma Symposium at the International Liver Cancer Association (ILCA) Annual Conference GlobeNewswire
Sep-04-19 06:32AM	Market Sentiment Around Loss-Making Celsion Corporation (NASDAQ:CLSN) Simply Wall St.
Aug-27-19 08:00AM	Celsion Announces Publication of Findings from Single-Site Study in China of ThermoDox® Plus RFA in the Journal of Cancer Research and Therapeutics GlobeNewswire
Aug-23-19 05:40AM	Edited Transcript of CLSN earnings conference call or presentation 15-Aug-19 3:00pm GMT Thomson Reuters StreetEvents
Aug-14-19 04:30PM	Celsion Corporation Reports Second Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Aug-13-19 08:01AM	Celsion Announces Publication of Results of National Institutes of Health (NIH) Analysis of ThermoDox® in Journal of Vascular and Interventional Radiology GlobeNewswire
Aug-09-19 08:30AM	Celsion's GEN-1 Immunotherapy Highlighted in Oppenheimer's Expert Call on Ovarian Cancer Treatment Landscape and Emerging Opportunities GlobeNewswire
Aug-08-19 08:30AM	Celsion Corporation to Hold Second Quarter 2019 Financial Results Conference Call on Thursday, August 15, 2019 GlobeNewswire
Aug-06-19 10:30AM	Will Celsion (CLSN) Report Negative Q2 Earnings? What You Should Know Zacks
Aug-05-19 09:00AM	Celsion Announces Data Lock for First Interim Analysis in OPTIMA Phase III Study of ThermoDox® in Primary Liver Cancer GlobeNewswire
07:31AM	Before You Buy Celsion Corporation (NASDAQ:CLSN), Consider Its Volatility Simply Wall St.
Jun-20-19 08:30AM	Celsion Announces IRB Approval to Begin a Clinical Study of ThermoDox® Plus High Intensity Focused Ultrasound in Breast Cancer Patients at University Medical Center Utrecht in the Netherlands GlobeNewswire
May-29-19 04:17AM	Edited Transcript of CLSN earnings conference call or presentation 15-May-19 3:00pm GMT Thomson Reuters StreetEvents
May-15-19 09:00AM	Celsion Corp. to Host Earnings Call ACCESSWIRE +6.07%
08:00AM	Celsion Corporation Reports First Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
May-13-19 09:30AM	Is Celsion (CLSN) Stock Outpacing Its Medical Peers This Year? Zacks
08:44AM	Blueprint Medicines (BPMC) Q1 Earnings & Sales Lag Estimates Zacks
May-10-19 10:11AM	Spectrum Pharma (SPPI) Q1 Earnings Lag Estimates, Revenues Nil Zacks
10:00AM	Puma Biotech (PBYI) Q1 Earnings Top, Nerlynx Disappoints Zacks
May-09-19 03:03PM	IVERIC bio's (ISEE) Q1 Loss Narrows, Gene Therapy in Focus Zacks
11:05AM	Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up Zacks
09:03AM	Arena Pharmaceuticals' (ARNA) Loss Widens in Q1 But Stock Up Zacks
May-08-19 05:00PM	Celsion Corporation to Hold First Quarter 2019 Financial Results Conference Call on Wednesday, May 15, 2019 GlobeNewswire
10:30AM	Will Celsion (CLSN) Report Negative Earnings Next Week? What You Should Know Zacks
May-07-19 05:50PM	Celsion (CLSN) Dips More Than Broader Markets: What You Should Know Zacks
May-01-19 05:50PM	Celsion (CLSN) Flat As Market Sinks: What You Should Know Zacks
Apr-26-19 11:11AM	Medicines Company (MDCO) Q1 Loss Narrows, Inclisiran in Focus Zacks -5.73%
10:59AM	AstraZeneca's (AZN) Q1 Earnings Beat, New Drugs Drive Sales Zacks
09:30AM	Is Celsion (CLSN) Outperforming Other Medical Stocks This Year? Zacks
Apr-25-19 09:31AM	Alexion (ALXN) Q1 Earnings Beat Estimates, Guidance Raised Zacks
Apr-17-19 08:14AM	Ultragenyx's (RARE) UX007 Gets Fast Track Status by FDA Zacks
08:00AM	Celsion Corporation Announces Issuance of New Patent for ThermoDox® GlobeNewswire
Apr-16-19 07:26PM	ProQR Initiates Dosing in Phase II/III Eye Disorder Study Zacks
Apr-12-19 08:30AM	Celsion Corporation to Participate in Two Investor Conferences in May 2019 GlobeNewswire
08:00AM	Celsion Corporation to Hold First Quarter 2019 Financial Results Conference Call on Wednesday, May 15, 2019 GlobeNewswire
Apr-11-19 12:34PM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Celsion Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Apr-08-19 08:43AM	Edited Transcript of CLSN earnings conference call or presentation 29-Mar-19 3:00pm GMT Thomson Reuters StreetEvents
Apr-03-19 09:00AM	Celsion (CLSN) Moves to Strong Buy: Rationale Behind the Upgrade Zacks +17.56%
Mar-29-19 08:00AM	Celsion Corporation Reports 2018 Financial Results GlobeNewswire
Mar-22-19 08:30AM	Celsion Corporation to Hold Year-End 2018 Financial Results Conference Call on Friday, March 29, 2019 GlobeNewswire
Mar-04-19 08:30AM	Celsion Announces GEN-1 Data Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium GlobeNewswire
Feb-21-19 04:30PM	Celsion Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Feb-01-19 07:30AM	Consolidated Research: 2019 Summary Expectations for Southwest Airlines, Southern Copper, SEI Investments, Forward Air, Cincinnati Financial, and Celsion Fundamental Analysis, Key Performance Indications GlobeNewswire
Jan-24-19 11:30AM	Celsion Corporation to Present at NobleConXV Noble Capital Markets 15th Annual Investor Conference GlobeNewswire
Jan-17-19 08:30AM	Celsion Announces Publication of ThermoDox® Study Results in Radiology GlobeNewswire +8.49%
Jan-15-19 08:30AM	Celsion Announces Presentation of GEN-1 Data at Upcoming ASCO-SITC Clinical Immuno-Oncology Symposium GlobeNewswire +6.22%
Dec-25-18 02:47PM	Edited Transcript of CLSN earnings conference call or presentation 15-Nov-18 4:00pm GMT Thomson Reuters StreetEvents
Dec-18-18 08:00AM	Data Monitoring Committee (DMC) Completes Planned Safety and Data Review of Celsions Phase III OPTIMA Study of ThermoDox® for Treatment of Primary Liver Cancer GlobeNewswire -8.33%
Dec-03-18 09:15AM	Celsion Receives $11.1 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program GlobeNewswire
Nov-21-18 02:53PM	Analysts Take Action on Health Care Stocks GuruFocus.com
Nov-14-18 04:30PM	Celsion Corporation Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Nov-08-18 09:15AM	Celsion Corporation to Hold Third Quarter 2018 Financial Results Conference Call on Thursday, November 15, 2018 GlobeNewswire
Oct-25-18 08:40AM	Report: Exploring Fundamental Drivers Behind The ExOne, Switch, Monotype Imaging, Celsion, TrueCar, and Sandstorm Gold New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Oct-24-18 09:25AM	Celsion Announces Progression-Free Survival Data From GEN-1 Phase I Immuno-Oncology Study of Patients with Stage III/IV Ovarian Cancer GlobeNewswire
Oct-22-18 09:20AM	Celsion Announces Publication Highlighting the Potential of Celsion's Gene-Mediated Immunotherapy to Improve Administration of IL-12 and Progression-Free Survival in Ovarian Cancer Patients GlobeNewswire -8.43%
Oct-03-18 05:15PM	Celsion Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Sep-17-18 08:30AM	Celsion Appoints Marianne Lambertson as Vice President of Communications and Investor Relations GlobeNewswire
Sep-16-18 02:22PM	The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs Benzinga
Sep-06-18 08:00AM	Celsion Announces First Patient Randomized in the Gene-Mediated Immunotherapy (GEN-1) Study of Newly Diagnosed Stage III/IV Ovarian Cancer Patients GlobeNewswire
Sep-05-18 08:00AM	Celsion Announces Enrollment Completion for Pivotal Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer GlobeNewswire -6.42%
07:30AM	Factors of Influence in 2018, Key Indicators and Opportunity within Aerie Pharmaceuticals, BioScrip, Celsion, Primoris Services, Cyclacel Pharmaceuticals, and Barnes Group New Research Emphasizes Economic Growth GlobeNewswire

Celsion Corporation, an integrated development clinical stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Martinez Alberto R Jr	Director	Feb 28	Buy	0.90	5,000	4,500	45,000	Feb 28 10:50 AM
Martinez Alberto R Jr	Director	Nov 20	Buy	1.42	6,000	8,520	40,000	Nov 20 11:28 AM
Fritz Frederick J.	Director	Nov 06	Buy	1.39	10,000	13,876	51,491	Nov 07 08:33 AM
Martinez Alberto R Jr	Director	Nov 04	Buy	1.61	4,000	6,440	34,000	Nov 04 02:40 PM
Fritz Frederick J.	Director	Aug 02	Buy	1.73	10,000	17,300	41,491	Aug 02 04:09 PM
Martinez Alberto R Jr	Director	Jul 25	Buy	1.76	6,000	10,560	30,000	Jul 25 01:27 PM
Fritz Frederick J.	Director	Jul 24	Buy	1.73	10,000	17,300	31,491	Jul 25 09:15 AM
CHURCH JEFFREY WAYNE	CFO	Jun 19	Buy	1.89	5,000	9,450	7,298	Jun 19 12:07 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience